Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2S)-2-([hydroxy[2-(4-hydroxyphenyl)ethoxy]phosphoryl]methyl)pentanedioic acid
-
-
(2S)-2-([[2-(4-fluorophenyl)ethoxy](hydroxy)phosphoryl]methyl)pentanedioic acid
-
-
(2S)-2-([[2-(4-[[N-(tert-butoxycarbonyl)glycyl]amino]phenyl)ethoxy](hydroxy)phosphoryl]methyl)pentanedioic acid
-
-
(2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid
(2S)-2-[([[(1S)-1,3-dicarboxypropyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[([[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]carbonyl)amino]pentanedioic acid
-
the inhibitor has the ability to reduce the perception of inflammatory pain
(2S)-2-[([[(1S)-1-carboxy-2-phenylethyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[([[(1S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[([[(1S)-1-carboxy-3-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid
-
-
(2S)-2-[([[(1S)-3-carboxy-1-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[([[(S)-carboxy(4-hydroxyphenyl)methyl]amino]carbonyl)amino]pentanedioic acid
-
-
(2S)-2-[[(2-[4-[(tert-butoxycarbonyl)amino]phenyl]ethoxy)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
-
(2S)-2-[[([(1S)-1-carboxy-3-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl]amino)carbonyl]amino]pentanedioic acid
-
-
(2S)-2-[[([(1S)-3-carboxy-1-[2-(2-cyanoethyl)-2H-tetrazol-5-yl]propyl]amino)carbonyl]amino]pentanedioic acid
-
-
(2S)-2-[[butyl(hydroxy)phosphorothioyl]amino]pentanedioic acid
-
-
(2S)-2-[[ethyl(hydroxy)phosphorothioyl]amino]pentanedioic acid
-
-
(2S)-2-[[hydroxy(2-phenylethoxy)phosphoryl]methyl]pentanedioic acid
-
-
(2S)-2-[[hydroxy(3-phenylpropoxy)phosphoryl]methyl]pentanedioic acid
-
-
(2S)-2-[[hydroxy(methyl)phosphorothioyl]amino]pentanedioic acid
-
-
(2S)-2-[[hydroxy(phenyl)phosphorothioyl]amino]pentanedioic acid
-
-
(2S)-2-[[hydroxy(phenyl)phosphorothioyl]oxy]pentanedioic acid
-
-
(2S)-2-[[hydroxy(phenyl)phosphoryl]amino]pentanedioic acid
-
-
(2S)-2-[[[2-[4-(acetylamino)phenyl]ethoxy](hydroxy)phosphoryl]methyl]pentanedioic acid
-
-
(2S,2'S,4R)-4-benzyl-N,N'-carbonyldiglutamic acid
-
-
(2S,2'S,4R,4'R)-4,4'-dibenzyl-N,N'-carbonyldiglutamic acid
-
-
(2S,2'S,4R,4'R)-N,N'-carbonyl-4,4'-dimethyldiglutamic acid
-
-
(2S,2'S,4S)-N,N'-carbonyl-4-methyldiglutamic acid
-
-
(2S,2'S,4S,4'S)-N,N'-carbonyl-4,4'-dimethyldiglutamic acid
-
-
(2S,3'S)-[[(3'-amino-3'-carboxy-propyl)-hydroxyphosphinoyl]methyl]-pentanedioic acid
-
EPE, a phosphapeptide transition state analog of glutamyl-glutamate
(2S,4R)-2-[([[(1S,3R)-1,3-dicarboxybutyl]amino]carbonyl)amino]-4-methylpentanedioic acid
-
-
(2S,4S)-2-[([[(1S,3S)-1,3-dicarboxybutyl]amino]carbonyl)amino]-4-methylpentanedioic acid
-
-
(4S)-4-[([[(1S)-3-carboxy-1-(2H-tetrazol-5-yl)propyl]amino]carbonyl)amino]-4-(2H-tetrazol-5-yl)butanoic acid
-
-
(9S,13S)-1-(3-iodophenyl)-3,11-dioxo-2,4,10,12-tetraazapentadecane-9,13,15-tricarboxylic acid
-
-
(R)-2-(3-mercaptopropyl)-pentanedioic acid
(R)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
(R)-2-(phosphonomethyl)-pentanedioic acid
(S)-2-(3-((R)-1-carboxy-(2-methylthio)ethyl)ureido)pentanedioic acid
DCMC
(S)-2-(3-((R)-1-carboxy-2-(4-fluorobenzylthio)ethyl)ureido)pentanedioic acid
DCFBC
(S)-2-(3-((S)-1-carboxy-(4-iodobenzamido)pentyl)ureido)pentanedioic acid
(S)-2-(3-((S)-1-carboxy-2-(4-hydroxy-3-iodophenyl)ethyl)ureido)pentanedioic acid
(S)-2-(3-((S)-1-carboxy-5-(1,2-dicarba-closo-dodecarboranylamido) pentyl)ureido)pentanedioic acid
-
(S)-2-(3-((S)-1-carboxy-5-(2-chlorobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(2-iodobenzylamino)pentyl)ureido)-pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-(4-bromophenyl)ureido)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-(4-chlorophenyl)ureido)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-(4-fluorophenyl)ureido)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid
(S)-2-(3-((S)-1-carboxy-5-(3-chlorobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-iodobenzylamino)pentyl)ureido)-pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(3-phenylureido)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-bromobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-chlorobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-fluorobenzylamino)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)-pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(4-iodobenzylamino)pentyl)ureido)pentanedioic acid
-
i.e. MIP-1072, the compound shows affinity to and uptake into prostate cancer cells, binding analysis, overview
(S)-2-(3-((S)-1-carboxy-5-(4-iodophenylsulfonamido)pentyl)-ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-5-(naphthalen-1-ylmethylamino)pentyl)-ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-5-(6-(4-(4-(4-acetylpiperazin-1-yl)phenyl)piperazin-1-yl)-N-(4-bromobenzyl)nicotinamido)-1-carboxypentyl)ureido)-pentanedioic acid
4200fold selectivity compared to glutamate carboxypeptidase III
(S)-2-(3-((S)-5-(6-(4-(4-(4-acetylpiperazin-1-yl)phenyl)piperazin-1-yl)nicotinamido)-1-carboxypentyl)ureido)pentanedioic acid
1400fold selectivity compared to glutamate carboxypeptidase III
(S)-2-(3-((S)-5-(benzylamino)-1-carboxypentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-((S)-5-(N-(4-bromobenzyl)-6-(4-(4-(4-(4-carboxy-3-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoyl)piperazin-1-yl)phenyl)-piperazin-1-yl)nicotinamido)-1-carboxypentyl)ureido)pentanedioic acid
1900fold selectivity compared to glutamate carboxypeptidase III
(S)-2-(3-((S)-5-(N-(4-bromobenzyl)-6-(4-(4-(4-(41-oxo-45-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10,13,16,19,22,25,28,31,34,37-dodecaoxa-40-azapentatetracontan-1-oyl)piperazin-1-yl)phenyl)piperazin-1-yl)nicotinamido)-1-carboxypentyl)ureido)pentanedioic acid
6600fold selectivity compared to glutamate carboxypeptidase III
(S)-2-(3-((S)-5-amino-1-carboxypentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-(4-iodobenzyl)ureido)pentanedioic acid
-
-
(S)-2-(3-mercaptopropyl)-pentanedioic acid
(S)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
(S)-2-(phosphonomethyl)-pentanedioic acid
(S)-2-[3-((S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)ureido]pentanedioic acid
(S)-2-[3-((S)-1-carboxy-2-phenylethyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
(S)-2-[3-((S)-1-carboxy-3-(methylsulfanyl)propyl)ureido]pentanedioic acid
(S)-2-[3-((S)-1-carboxy-3-methylbutyl)ureido]pentanedioic acid
(S)-2-[3-((S)-1-carboxy-3-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-3-carboxy-1-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-3-carboxy-1-[1-(2-cyanoethyl)-1H-tetrazol-5-yl]propyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-alpha-carboxy-4-hydroxybenzyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-alpha-carboxybenzyl)ureido]pentanedioic acid
-
-
(S)-2-[3-(S)-(1,3-dicarboxypropyl)ureido]pentanedioinc acid
(S)-alpha-ethylglutamate
-
specific group II metabotropic glutamate receptor antagonist, in vivo activity
(S,S)-4,4'-bis[1-(2-cyanoethyl)-1H-tetrazol-5-yl]-2,2'-ureylenedibutyric acid
-
-
(S,S)-4,4'-bis[1-(2-cyanoethyl)-1H-tetrazol-5-yl]-4,4'-ureylenedibutyric acid
-
-
(S,S)-4,4'-di-(1H-tetrazol-5-yl)-2,2'-ureylenedibutyric acid
-
-
(S,S)-4,4'-di-(1H-tetrazol-5-yl)-4,4'-ureylenedibutyric acid
-
-
(S,S)-N,N'-carbonyl-2,2'-dimethyldiglutamic acid
-
-
(t-Bu)Cys-PSI[C-O]-Glu
-
IC50: 29 nM
(Z)-N-(N-Acetyldehydroaspartyl)-L-Glu
-
-
1,10-phenanthroline
-
1 mM, 90% inhibition
2-(2-carboxy-5-mercaptopentyl)benzoic acid
-
IC50: 1700 nM
2-(3-carbamoylbenzyl)-5-mercaptopentanoic acid
-
IC50: 2200 nM
2-(3-carboxybenyl)succinic acid
-
IC50: 0.015 mM
2-(3-cyanobenzyl)-5-mercaptopentanoic acid
-
IC50: 1800 nM
2-(3-hydroxybenzyl)-3-phosphonopropanoic acid
-
IC50: 508 nM
2-(3-mercaptopropyl)-pentanedioic acid
2-(3-mercaptopropyl)pentanedioic acid
2-(3-sulfanylpropyl)pentanedioic acid
-
i.e. GPI-5693, attenuates cocaine-induced conditioned place preference
2-(phosphonomethyl) pentanedioic acid
inhibitor completely blocks N-acetylaspartylglutamate cleavage activity but not Amyloid-beta degradation
2-(phosphonomethyl)-4-(5H-tetrazol-5-yl)butanoic acid
-
IC50: 175 nM
2-(phosphonomethyl)-pentanedioic acid
2-(phosphonomethyl)hexanedioic acid
-
IC50: 185 nM
2-(phosphonomethyl)hexanoic acid
-
IC50: 185 nM
2-(phosphonomethyl)pentandioic acid
10fold selectivity compared to glutamate carboxypeptidase III
2-(phosphonomethyl)pentanedioic acid
2-(Phosphonomethyl)pentanoate
-
-
2-(phosphonomethyl)succinic acid
-
IC50: 2200 nM
2-([hydroxy[3-(trifluoromethyl)benzyl]phosphoryl]methyl)pentanedioic acid
-
IC50: 55 nM
2-([hydroxy[hydroxy(phenyl)methyl]phosphoryl]methyl)pentanedioic acid
-
IC50: 55 nM
2-([hydroxy[hydroxy(pyridin-4-yl)methyl]phosphoryl]methyl)pentanedioic acid
-
IC50: 10 nM
2-amino-3-(3,5-dioxo[1,2,4]oxadiazolidin-2-yl)propionic acid
-
i.e. quisqualic acid, a glutamate-like inhibitor of GCPIII and GCPII
2-benzyl-3-phosphonopropanoic acid
-
IC50: 548 nM
2-benzyl-5-mercaptopentanoic acid
-
IC50: 1400 nM
2-oxoglutarate
-
0.1 mM, 46% inhibition
2-phosphonomethyl-pentanedoic acid
-
2-PMPA
2-[(hydroxy[[(4-methoxyphenyl)amino]methyl]phosphoryl)methyl]pentanedioic acid
-
IC50: 3 nM
2-[[(2,4-dicarboxybutyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 0.5 nM
2-[[(2-carboxy-3-phenylpropyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 2 nM
2-[[(2-carboxy-4-phenylbutyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 2 nM
2-[[(2-carboxyethyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 1 nM
2-[[(2-carboxypropyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 1.5 nM
2-[[(2-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 156 nM
2-[[(3,5-difluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 49 nM
2-[[(3-aminobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 143 nM
2-[[(3-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 70 nM
2-[[(4-fluorobenzyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 64 nM
2-[[(anilinomethyl)(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 4 nM
2-[[benzyl(hydroxy)phosphoryl]methyl]pentanedioic acid
2-[[hydroxy(2-phenylethyl)phosphoryl]methyl]pentanedioic acid
2-[[hydroxy(3-nitrobenzyl)phosphoryl]methyl]pentanedioic acid
-
IC50 59 nM
2-[[hydroxy(3-phenylpropyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 230 nM
2-[[hydroxy(4-methoxybenzyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 90 nM
2-[[hydroxy(4-methylbenzyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 68 nM
2-[[hydroxy(pentafluorobenzyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 82 nM. Significantly prevents neurodegeneration in a middle cerebral artery occlusion model of cerebral ischemia. In the chronic constrictive model of neuropathic pain, the inhibitor sifnificantly attenuats the hypersensitivity observed with saline-treated animals
2-[[hydroxy(phenyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 2930 nM
2-[[hydroxy(propyl)phosphoryl]methyl]pentanedioic acid
2-[[[(3-fluorophenyl)(hydroxy)methyl](hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 16 nM
2-[[[(benzylamino)methyl](hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 59 nM
2-[[[3,5-bis(trifluoromethyl)benzyl](hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 55 nM
2-[[[3-(benzyloxy)-2-methyl-3-oxopropyl](hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 95 nM
2-{[2-Carboxy-3-(4-methoxy-phenylamino)-propyl]-hydroxy-phosphinoylmethyl}-pentanedioic acid
-
IC50: 3 nM
3-(1-carboxy-4-mercaptobutoxy)benzoic acid
-
IC50: 14 nM
3-(2-carbamoyl-5-mercaptopentyl)benzoic acid
-
IC50: 640 nM
3-(2-carboxy-3-hydroxycarbamoylpropyl)benzoic acid
-
IC50: 0.015 mM
3-(2-carboxy-3-phosphonopropyl)benzoic acid
-
IC50: 120 nM
3-(2-carboxy-5-mercaptopentyl)benzoic acid
-
IC50: 15 nM
3-(2-carboxy-5-mercaptopentyl)benzoic acid methyl ester
-
IC50: 2700 nM
3-(2-carboxy-5-mercaptosulfanylpentyl)benzoic acid
-
IC50: 0.02 mM
3-(2-carboxy-5-tritylsulfanylpentyl)benzoic acid
-
IC50: 0.02 mM
3-(2-oxotetrahydro-thiopyran-3-yl)propionic acid
-
prodrug of inhibitor 2-(3-mercaptopropyl)pentanedioic acid
3-(3-mercaptopropyl)pentanedioic acid
-
presynaptic action of enzyme inhibition, enzyme inhibition depresses mossy fiber-CA3 synaptic transmission
3-(5-mercapto-2-methoxycarbonylpentyl)benzoic acid
-
IC50: 730 nM
3-[(1-carboxy-4-mercaptobutyl)thio]benzoic acid
-
IC50: 32 nM
3-[2-carboxy-3-(hydroxypentafluorophenylmethylphosphinoyl)propyl]benzoic acid
-
IC50: 2400 nM
4,4'-phosphinicobis(butane-1,3-dicarboxylic acid)
4-(2-carboxy-5-mercaptopentyl)benzoic acid
-
IC50: 63 nM
4-(3-hydroxyphenyl)-2-(phosphonomethyl)butanoic acid
-
IC50: 508 nM
4-cyano-2-(phosphonomethyl)butanoic acid
-
IC50: 335 nM
4-phenyl-2-(phosphonomethyl)butanoic acid
-
IC50: 199 nM
4-[(2-(R))-2-carboxy-5-(oxidanylamino)-5-oxidanylidene-pentyl]benzoic acid
-
4-[(2-(S))-2-carboxy-5-(oxidanylamino)-5-oxidanylidene-pentyl]benzoic acid
-
4-[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphoryl]-methyl]-5-[[(isopropoxycarbonyl)oxy]methoxy]-5-oxopentanoic acid
5-oxoheptane-1,3,7-tricarboxylic acid
-
0.1 mM, 35% inhibition
5-oxononane-1,3,7,9-tetracarboxylic acid
-
inhibitor possesses mGluR3 agonist activity
Ala-Glu
-
0.0061 mM, 50% inhibition
Asp-Ala
-
0.1 mM, 26% inhibition
Asp-Asp
-
0.1 mM, 42% inhibition
Asp-Phe
-
0.1 mM, 22% inhibition
Asp-PSI[C-O-S]-Glu
-
IC50: 0.0461 mM
Asp-PSI[C-O]-Asp
-
IC50: 0.0038 mM
Asp-PSI[S]-Asp
-
0.1 mM, 42% inhibition
aspartate
-
0.1 mM, 42% inhibition
bestatin
-
0.29 mM, 79% inhibition
Cys-PSI[C-O-S]-Glu
-
IC50: 6.9 nM
cysteate
-
0.1 mM, 40% inhibition
cysteine sulfinate
-
0.1 mM, 42% inhibition
D-Glu-D-Glu
-
0.1 mM, 50% inhibition
D-Glu-PSI[C-O]-D-Glu
-
0.1 mM, 67% inhibition
D-Glu-PSI[C-O]-Glu
-
0.001 mM, 25% inhibition
diphenyl 2-[[[2-[4-([[7-(diethylamino)-2-oxo-2H-chromen-3-yl]carbamoyl]amino)phenyl]ethoxy](hydroxy)phosphoryl]methyl]pentanedioate
-
-
dithiothreitol
-
1 mM, 94.8% inhibition
DKFZ-PSMA-11
720fold selectivity compared to glutamate carboxypeptidase III
DUPA
-
enzyme active site binding structure, docking and modelling, detailed overview
Glu-Asp
-
0.1 mM, 27% inhibition
Glu-PSI[C-O-C-O]-Glu
-
0.001 mM, 9% inhibition
Glu-PSI[C-O]-Glu
-
IC50: 47 nM
glutathione
-
i.e. gamma-Glu-Cys-Gly, 0.019 mM, 50% inhibition
Gly-Gly-Glu
-
0.00098 mM, 50% inhibition
Gly-PSI[C-O-S]-Glu
-
0.001 mM, 46% inhibition
GPI 5693
-
i.e. (R,S)-2-(3-mercaptopropyl)-pentanedioic acid or 2-MPPA, pharmacokinetics and safety of the NAALADase-inhibitor and its effects on the central nervous system after application in vivo, overview
GPI-16476
-
enantiomer of GPI-5693
GPI-16477
-
enantiomer of GPI-5693
GPI-18431
-
enzyme active site binding structure, docking and modelling, detailed overview
Ibotenate
-
0.1 mM, 45% inhibition
iodoacetate
-
1 mM, 38% inhibition
L-2-Amino-4-phosphonobutanoate
-
0.1 mM, 37% inhibition
N-(3,4-Dicarboxybutanoyl)glutamic acid
-
-
N-(4-fluorobenzoyl)-L-isoleucyl-O-[[[(1S)-1,3-dicarboxypropyl]amino](hydroxy)phosphoryl]-L-serine
-
N-(4-fluorobenzoyl)-L-valyl-O-[[[(1S)-1,3-dicarboxypropyl]amino](hydroxy)phosphoryl]-L-serine
-
N-(Dicarboxymethyl)acetylglutaminic acid
-
-
N-(tert-butoxycarbonyl)glycyl-N-[4-[2-([[(2S)-2,4-dicarboxybutyl](hydroxy)phosphoryl]oxy)ethyl]phenyl]-L-prolinamide
-
-
N-(tert-butoxycarbonyl)glycylglycyl-N-[4-[2-([[(2S)-2,4-dicarboxybutyl](hydroxy)phosphoryl]oxy)ethyl]phenyl]glycinamide
-
-
N-([(1S)-1-carboxy-5-([(4-iodophenyl)carbonyl]amino)pentyl]carbamoyl)-L-glutamic acid
P1'-diversified urea-based inhibitor, in complex with enzyme PDB entry 3D7H
N-2-([(1S)-1-carboxy-2-(furan-2-yl)ethyl]carbamoyl)-N-6-(4-iodobenzoyl)-L-lysine
P1'-diversified urea-based inhibitor, in complex with enzyme PDB entry 4OC3
N-2-([(1S)-1-carboxybut-3-yn-1-yl]carbamoyl)-N-6-(4-iodobenzoyl)-L-lysine
P1'-diversified urea-based inhibitor, in complex with enzyme PDB entry 4OC2
N-Acetyl-Asp-Gln
-
0.1 mM, 49% inhibition
N-Acetyl-Asp-Glu-Asp
-
0.1 mM, 49% inhibition
N-Acetyl-Asp-Ser-Gly
-
0.1 mM, 37% inhibition
N-Acetyl-beta-L-Asp-L-Glu
N-Acetyl-Glu-Asp
-
0.036 mM, 50% inhibition
N-Acetyl-Glu-Glu
-
0.00031 mM, 50% inhibition
N-acetyl-L-Asp
-
0.1 mM, 38% inhibition
N-Acetyl-L-Asp-L-Glu
-
0.00054 mM, 50% inhibition
N-acetyl-L-Glu
-
0.058 mM, 50% inhibition
N-[(2-benzamidoethoxy)(hydroxy)phosphoryl]-L-glutamic acid
-
N-[4-carboxy-3-(carboxymethyl)-3-hydroxybutanoyl]-L-glutamic acid
N-[hydroxy(4-phenylbutoxy)phosphoryl]-L-glutamic acid
-
N-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]-L-glutamic acid
N-[[(1S)-1-carboxy-3-(methylsulfanyl)propyl]carbamoyl]-L-glutamic acid
N-[[(1S)-1-carboxy-3-methylbutyl]carbamoyl]-L-glutamic acid
N-[[(1S)-1-carboxy-5-(4-iodobenzamido)pentyl]carbamoyl]-L-glutamic acid
N-[[(1S)-1-carboxy-5-([5-[3-(3-[[[2-[[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl](carboxymethyl)amino]ethyl](carboxymethyl)amino]methyl]-4-hydroxyphenyl)propanamido]pentanoyl]amino)pentyl]carbamoyl]-L-glutamic acid
N-[[(1S)-5-([(4-bromophenyl)methyl][6-[4-(4-[4-[4-carboxy-3-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoyl]piperazin-1-yl]phenyl)piperazin-1-yl]pyridine-3-carbony]amino)-1-carboxypentyl]carbamoyl]-L-glutamic acid
N-[[(1S)-5-acetamido-1-carboxypentyl]carbamoyl]-L-glutamic acid
N-[[(1S)-5-[acetyl[(4-bromophenyl)methyl]amino]-1-carboxypentyl]carbamoyl]-L-glutamic acid
N-[[(2R)-2-benzamido-2-carboxyethoxy](hydroxy)phosphoryl]-L-glutamic acid
-
N-[[(2S)-2-benzamido-2-carboxyethoxy](hydroxy)phosphoryl]-L-glutamic acid
-
N-[[(2S)-2-[[(6S)-6-amino-6-carboxy-3-oxohexyl]amino]-2-carboxyethoxy](hydroxy)phosphoryl]-L-glutamic acid
-
N-[[([1,1'-biphenyl]-4-yl)methoxy](hydroxy)phosphoryl]-L-glutamic acid
-
N-[[[(1S)-1-carboxy-3-methylbutyl]amino]carbonyl]-L-glutamic acid
i.e. ZJ-43. 160fold selectivity compared to glutamate carboxypeptidase III
Phe-Glu
-
0.077 mM, 50% inhibition
puromycin
-
0.5 mM, 55% inhibition
pyroglutamate
-
0.1 mM, 27% inhibition
pyropheophorbide-a conjugate
-
i.e. Ppa-2 conjugate, non-specificity of unconjugated Ppa, conjugation of a peptidomimetic inhibitor of PSMA to the porphyrinic PS, pyropheophorbide-a gives
quinolinate
-
0.1 mM, 41% inhibition
S-2-((2-(S-4-(4-18F-fluorobenzamido)-4-carboxybutanamido)-S-2-carboxyethoxy)hydroxyphosphorylamino)-pentanedioic acid
-
-
S-2-((2-(S-4-amino-4-carboxybutanamido)-S-2-carboxyethoxy)-hydroxyphosphorylamino)-pentanedioic acid
-
phosphoramidate
Serine O-sulfate
-
0.042 mM, 50% inhibition
t-BuNHC(O)-Glu
-
0.001 mM, 10% inhibition
Tyr-Glu
-
0.1 mM, 45% inhibition
Val-Glu-Glu
-
0.036 mM, 50% inhibition
ZJ-43
-
i.e. (S)-2-[3-((S)-1-carboxy-3-methylbutyl)ureido]pentanedioic acid, the inhibitor enhances extracellular NAAG levels and reduces extracellular levels of amino acids neurotransmitter following traumatic brain injury in vivo
ZJ43
-
i.e. (S)-2-[3-((S)-1-carboxy-3-methylbutyl)ureido]pentanedioic acid
[HO2C(CH2)2CH(CO2H)CH2]2P(O)(OH)
-
-
(2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid
-
(2S)-2-amino-3-(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)propanoic acid
-
(R)-2-(3-mercaptopropyl)-pentanedioic acid
-
equally potent as the S-isomer, 0.000085 mM
(R)-2-(3-mercaptopropyl)-pentanedioic acid
-
antinociceptide effects in the chronic constriction injury model, cell culture model of cerebral ischemia
(R)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
-
40fold less potent than the S-isomer, IC50: 0.0014 mM
(R)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
-
neuroprotective effects in the middle cerebral artery occlusion model, cell culture model of cerebral ischemia
(R)-2-(phosphonomethyl)-pentanedioic acid
-
less potent than the S-isomer, IC50: 0.000030 mM
(R)-2-(phosphonomethyl)-pentanedioic acid
-
-
(S)-2-(3-((S)-1-carboxy-(4-iodobenzamido)pentyl)ureido)pentanedioic acid
DCIBzL
(S)-2-(3-((S)-1-carboxy-(4-iodobenzamido)pentyl)ureido)pentanedioic acid
830fold selectivity compared to glutamate carboxypeptidase III
(S)-2-(3-((S)-1-carboxy-2-(4-hydroxy-3-iodophenyl)ethyl)ureido)pentanedioic acid
DCIT
(S)-2-(3-((S)-1-carboxy-2-(4-hydroxy-3-iodophenyl)ethyl)ureido)pentanedioic acid
-
DCIT
(S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid
-
i.e. MIP-1095, the compound shows affinity to and uptake into prostate cancer cells, binding analysis, overview
(S)-2-(3-((S)-1-carboxy-5-(3-(4-iodophenyl)ureido)pentyl)ureido)pentanedioic acid
-
-
(S)-2-(3-mercaptopropyl)-pentanedioic acid
-
equally potent as the R-isomer, 0.000067 mM
(S)-2-(3-mercaptopropyl)-pentanedioic acid
-
antinociceptide effects in the chronic constriction injury model, cell culture model of cerebral ischemia
(S)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
-
40fold more potent than the R-isomer, IC50: 0.000034 mM
(S)-2-(hydroxypentafluorophenylmethyl-phosphinoylmethyl)pentanedioic acid
-
neuroprotective effects in the middle cerebral artery occlusion model, cell culture model of cerebral ischemia
(S)-2-(phosphonomethyl)-pentanedioic acid
-
more potent than the R-isomer, IC50: 0.0000001 mM
(S)-2-(phosphonomethyl)-pentanedioic acid
-
-
(S)-2-[3-((S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)ureido]pentanedioic acid
-
i.e. inhibitor ZJ17
(S)-2-[3-((S)-1-carboxy-2-(4-hydroxyphenyl)ethyl)ureido]pentanedioic acid
-
i.e. inhibitor ZJ17
(S)-2-[3-((S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
-
-
(S)-2-[3-((S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
-
i.e. inhibitor ZJ38
(S)-2-[3-((S)-1-carboxy-3-(1H-tetrazol-5-yl)propyl)ureido]pentanedioic acid
-
i.e. inhibitor ZJ38
(S)-2-[3-((S)-1-carboxy-3-(methylsulfanyl)propyl)ureido]pentanedioic acid
-
i.e. inhibitor ZJ11
(S)-2-[3-((S)-1-carboxy-3-(methylsulfanyl)propyl)ureido]pentanedioic acid
-
i.e. inhibitor ZJ11
(S)-2-[3-((S)-1-carboxy-3-methylbutyl)ureido]pentanedioic acid
-
i.e. inhibitor ZJ43
(S)-2-[3-((S)-1-carboxy-3-methylbutyl)ureido]pentanedioic acid
-
i.e. inhibitor ZJ43
(S)-2-[3-(S)-(1,3-dicarboxypropyl)ureido]pentanedioinc acid
-
-
(S)-2-[3-(S)-(1,3-dicarboxypropyl)ureido]pentanedioinc acid
-
-
2-(3-mercaptopropyl)-pentanedioic acid
-
2-MPPA, specific, potent, competitive inhibition, has higher oral bioavailability compared to 2-PMPA, acts neuroprotective in vivo, e.g. in case of ischemic stroke, and provides analgesia
2-(3-mercaptopropyl)-pentanedioic acid
-
i.e. 2-MPPA, IC50: 90 nM
2-(3-mercaptopropyl)-pentanedioic acid
-
i.e. 2-MPPA or GPI5693
2-(3-mercaptopropyl)-pentanedioic acid
-
2-MPPA, prevents morphine tolerance without affecting the acute morphine antinociception in vivo
2-(3-mercaptopropyl)-pentanedioic acid
-
2-MPPA, specific, potent, competitive inhibition, acts neuroprotective in vivo, e.g. in case of ischemic stroke, and provides analgesia
2-(3-mercaptopropyl)-pentanedioic acid
-
i.e. 2-MPPA or GPI5693
2-(3-mercaptopropyl)pentanedioic acid
-
IC50: 90 nM. Orally bioavailable in rats
2-(3-mercaptopropyl)pentanedioic acid
-
orally bioavailable inhibitor
2-(3-mercaptopropyl)pentanedioic acid
-
in rat liver microsomes, 2-(3-mercaptopropyl)pentanedioic acid is gradually produced from 3-(2-oxotetrahydro-thiopyran-3-yl)propionic acid, a thiolactone derived from the compound. 2-(3-Mercaptopropyl)pentanedioic acid is detected in plasma at concentrations well above its IC50 value for GCPII following oral administration of 3-(2-oxotetrahydro-thiopyran-3-yl)propionic acid in rats
2-(phosphonomethyl)-pentanedioic acid
-
2-PMPA
2-(phosphonomethyl)-pentanedioic acid
-
2-PMPA, specific, potent, competitive inhibition, acts neuroprotective in vivo, e.g. in case of ischemic stroke, and provides analgesia
2-(phosphonomethyl)-pentanedioic acid
i.e. 2-PMPA
2-(phosphonomethyl)-pentanedioic acid
-
i.e. 2-PMPA
2-(phosphonomethyl)-pentanedioic acid
2-PMPA, GCPIII IC50: 94 nM, GCPII IC50: 6.74 nM
2-(phosphonomethyl)-pentanedioic acid
-
2-PMPA
2-(phosphonomethyl)-pentanedioic acid
-
2-PMPA, specific GCPII inhibitor, in vivo activity
2-(phosphonomethyl)-pentanedioic acid
-
-
2-(phosphonomethyl)-pentanedioic acid
-
2-PMPA, specific, potent, competitive inhibition, acts neuroprotective in vivo, e.g. in case of ischemic stroke, and provides analgesia
2-(phosphonomethyl)-pentanedioic acid
-
i.e. 2-PMPA, enzyme inhibition protects the rats in vivo against ischemic injury to the brain and spinal cord, and hypoxic and metabolic injury to neuronal cells in culture
2-(phosphonomethyl)-pentanedioic acid
-
i.e. 2-PMPA
2-(phosphonomethyl)pentanedioic acid
-
potent inhibitor, robust neuroprotective efficacy in many neurological disease models
2-(phosphonomethyl)pentanedioic acid
-
competitive
2-(phosphonomethyl)pentanedioic acid
-
-
2-(phosphonomethyl)pentanedioic acid
-
2-PMPA
2-(phosphonomethyl)pentanedioic acid
completely blocks the NAAG hydrolysis without any effect on amyloid-beta degradation
2-(phosphonomethyl)pentanedioic acid
-
2-(phosphonomethyl)pentanedioic acid
-
2-(phosphonomethyl)pentanedioic acid
potent inhibitor, robust neuroprotective efficacy in many neurological disease models
2-(phosphonomethyl)pentanedioic acid
-
IC50: 5.1 nM
2-(phosphonomethyl)pentanedioic acid
-
IC50: 0.3 nM
2-(phosphonomethyl)pentanedioic acid
-
requires long-term daily dosing
2-(phosphonomethyl)pentanedioic acid
-
i.e. 2-PMPA, inhibits cocaine-induced behavioural sensitization
2-(phosphonomethyl)pentanedioic acid
-
i.e. 2-PMPA, a N-acetylated-alpha-linkedacidic dipeptidase inhibitor, attenuates cocaine self-administration and cocaine-induced reinstatement of drug seeking of rats
2-(phosphonomethyl)pentanedioic acid
-
2-[[benzyl(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 70 nM
2-[[benzyl(hydroxy)phosphoryl]methyl]pentanedioic acid
-
IC50: 53 nM
2-[[hydroxy(2-phenylethyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 150 nM
2-[[hydroxy(2-phenylethyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 149 nM
2-[[hydroxy(propyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 560 nM
2-[[hydroxy(propyl)phosphoryl]methyl]pentanedioic acid
-
IC50: 360 nM
4,4'-phosphinicobis(butane-1,3-dicarboxylic acid)
-
i.e. PBDA, effects of stereoisomers, overview
4,4'-phosphinicobis(butane-1,3-dicarboxylic acid)
-
i.e. PBDA
4-[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphoryl]-methyl]-5-[[(isopropoxycarbonyl)oxy]methoxy]-5-oxopentanoic acid
-
the orally bioavailable prodrug affords excellent release of 2-phosphonomethylpentanedioic acid following oral administration in both mice and dog
4-[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphoryl]-methyl]-5-[[(isopropoxycarbonyl)oxy]methoxy]-5-oxopentanoic acid
the orally bioavailable prodrug affords excellent release of 2-phosphonomethylpentanedioic acid following oral administration in both mice and dog
Asp-Glu
-
0.0024 mM, 50% inhibition
diazabicycloalkane
-
cis- and trans-isomers, dipeptide mimetic
-
diazabicycloalkane
-
cis- and trans-isomers, dipeptide mimetic
-
EDTA
-
EDTA
-
1 mM, 96.3% inhibition
EGTA
-
1 mM, 92% inhibition
gamma-Glu-Glu
-
0.0095 mM, 50% inhibition
Glu-Glu
-
0.00075 mM, 50% inhibition
Glu-Glu-Glu
-
0.062 mM, 50% inhibition
Gly-Glu
-
0.008 mM, 50% inhibition
GPI5232
-
i.e. 2-([((hydroxypentyfluorophenyl)methyl)phosphinoyl]methyl)pentanedioic acid
GPI5232
-
a 2-PMPA analogue
GPI5232
-
i.e. 2-([((hydroxypentyfluorophenyl)methyl)phosphinoyl]methyl)pentanedioic acid
L-Glu
-
-
L-Glu
-
0.032 mM, 50% inhibition
N-Acetyl-beta-L-Asp-L-Glu
-
-
N-Acetyl-beta-L-Asp-L-Glu
-
-
N-[4-carboxy-3-(carboxymethyl)-3-hydroxybutanoyl]-L-glutamic acid
-
N-[4-carboxy-3-(carboxymethyl)-3-hydroxybutanoyl]-L-glutamic acid
-
N-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]-L-glutamic acid
-
i.e. inhibitor ZJ17, antinociceptive effect of the inhibitor in the rat formalin test and the rat neuropathic pain model, overview
N-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]-L-glutamic acid
-
i.e. inhibitor ZJ17, antinociceptive effect of the inhibitor in the rat formalin test and the rat neuropathic pain model, agonist and antagonist activity on recombinantly expressed metabotropic glutamate receptor, overview
N-[[(1S)-1-carboxy-3-(methylsulfanyl)propyl]carbamoyl]-L-glutamic acid
-
i.e. inhibitor ZJ11, antinociceptive effect of the inhibitor in the rat formalin test and the rat neuropathic pain model, overview
N-[[(1S)-1-carboxy-3-(methylsulfanyl)propyl]carbamoyl]-L-glutamic acid
-
i.e. inhibitor ZJ11, antinociceptive effect of the inhibitor in the rat formalin test and the rat neuropathic pain model, agonist and antagonist activity on recombinantly expressed metabotropic glutamate receptor, overview
N-[[(1S)-1-carboxy-3-methylbutyl]carbamoyl]-L-glutamic acid
-
i.e. inhibitor ZJ43, antinociceptive effect of the inhibitor in the rat formalin test and the rat neuropathic pain model, overview
N-[[(1S)-1-carboxy-3-methylbutyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-1-carboxy-3-methylbutyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-1-carboxy-3-methylbutyl]carbamoyl]-L-glutamic acid
-
i.e. inhibitor ZJ43, antinociceptive effect of the inhibitor in the rat formalin test and the rat neuropathic pain model, agonist and antagonist activity on recombinantly expressed metabotropic glutamate receptor, overview
N-[[(1S)-1-carboxy-5-(4-iodobenzamido)pentyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-1-carboxy-5-(4-iodobenzamido)pentyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-1-carboxy-5-([5-[3-(3-[[[2-[[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl](carboxymethyl)amino]ethyl](carboxymethyl)amino]methyl]-4-hydroxyphenyl)propanamido]pentanoyl]amino)pentyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-1-carboxy-5-([5-[3-(3-[[[2-[[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl](carboxymethyl)amino]ethyl](carboxymethyl)amino]methyl]-4-hydroxyphenyl)propanamido]pentanoyl]amino)pentyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-5-([(4-bromophenyl)methyl][6-[4-(4-[4-[4-carboxy-3-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoyl]piperazin-1-yl]phenyl)piperazin-1-yl]pyridine-3-carbony]amino)-1-carboxypentyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-5-([(4-bromophenyl)methyl][6-[4-(4-[4-[4-carboxy-3-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoyl]piperazin-1-yl]phenyl)piperazin-1-yl]pyridine-3-carbony]amino)-1-carboxypentyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-5-acetamido-1-carboxypentyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-5-acetamido-1-carboxypentyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-5-[acetyl[(4-bromophenyl)methyl]amino]-1-carboxypentyl]carbamoyl]-L-glutamic acid
-
N-[[(1S)-5-[acetyl[(4-bromophenyl)methyl]amino]-1-carboxypentyl]carbamoyl]-L-glutamic acid
-
Quisqualic acid
-
-
Quisqualic acid
-
0.00048 mM, 50% inhibition
VA-033
-
i.e. 2-([(benzyloxy)phosphonyl]methyl)pentanedioic acid
VA-033
-
i.e. 2-([(benzyloxy)phosphonyl]methyl)pentanedioic acid
additional information
-
the androgen receptor negatively regulates the enzyme expression
-
additional information
-
design of urea-based NAAG peptidase-specific inhibitors, IC50 values of the stereoisomers, inhibition strategies, overview, inhibitors are used in therapy of neurological disorders, overview, construction of a human traumatic brain injury, TBI, to test inhibitor effects, overview
-
additional information
-
GCPIII enzyme-inhibitor interactions and the architecture of the S1' pocket, overview
-
additional information
-
design and synthesis of a series of glutamate-urea-X heterodimeric inhibitors of PSMA, where X is epsilon-N-(o-I, m-I, p-I, p-Br, o-Cl, m-Cl, p-Cl, p-F, H)-benzyl-Lys and epsilon-(p-I, p-Br, p-Cl, p-F, H)-phenylureido-Lys, overview. PSMA binding of the benzyllysine series is significantly affected by the nature of the halogen substituent. The halogen atom has little affect on the binding affinity in the para-substituted phenylureido-Lys series
-
additional information
-
inhibitor in vivo distribution studies in mice bearing either PSMA-positive LNCaP or PSMA-negative PC-3 tumors, overview
-
additional information
-
phosphoramidate peptidomimetic PSMA inhibitors are capable of both cell-surface labeling of prostate cancer cells and intracellular delivery. Use of a PSMA inhibitor-conjugate of pyropheophorbide-a, i.e. Ppa-conjugate 2, for targeted photodynamic therapy to achieve apoptosis in PSMA and LNCaP cells, overview
-
additional information
pharmacophore analysis followed by QSAR studies proposes a N-acetyl aspartyl glutamate-analogue as the most potent inhibitor of the enzyme, effective across all the genetic variants of glutamate carboxypeptidase II. This molecule satisfies Lipinski rule of five and rule of three for drug-likeliness. Being a N-acetyl aspartyl glutamate-analogue, this molecule might confer neuroprotection by inhibiting glutamatergic neurotransmission mediated by N-acetylated alpha-linked acidic dipeptidase (NAALADase), a splice variant of glutamate carboxypeptidase II
-
additional information
-
the androgen receptor negatively regulates the enzyme expression
-
additional information
-
N-[N-((S)-1,3-dicarboxypropyl)carbamoyl]-S-3-iodo-L-tyrosine, i.e. DCIT, is a potent antagonist of the enzyme activity
-
additional information
-
glutamate receptor antagonists reduce the enzyme activity in vivo, overview
-
additional information
-
not inhibitory are pepstatin, iodoacetamide, amastatin
-
additional information
-
N-acetyl-L-Asp-D-Glu
-
additional information
-
N-acetyl-L-Asp-D-Glu
-
additional information
-
GCPII inhibitors are attractive candidates for clinical treatment trials in amylotrophic lateral sclerosis
-
additional information
-
design of urea-based NAAG peptidase-specific inhibitors, inhibition strategies, overview, construction of a stroke rat model and traumatic brain injury, TBI, to test inhibitor effects, overview
-
additional information
-
N-[N-((S)-1,3-dicarboxypropyl)carbamoyl]-S-3-iodo-L-tyrosine, i.e. DCIT, is a potent antagonist of the enzyme activity
-